世界の血友病A・B組換え因子補充療法市場規模・現状・予測2021-2027

【英語タイトル】Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, Status and Forecast 2021-2027

QYResearchが出版した調査資料(QY21APR2770)・商品コード:QY21APR2770
・発行会社(調査会社):QYResearch
・発行日:2021年4月(※2024年版があります。お問い合わせください)
・ページ数:92
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査資料では、血友病A・B組換え因子補充療法の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(血友病A、血友病B)、用途別市場規模(病院、クリニック、外来手術センター)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・血友病A・B組換え因子補充療法の市場動向
・企業の競争状況、市場シェア
・血友病A・B組換え因子補充療法の種類別市場規模(血友病A、血友病B)
・血友病A・B組換え因子補充療法の用途別市場規模(病院、クリニック、外来手術センター)
・血友病A・B組換え因子補充療法の北米市場規模2016-2027(アメリカ、カナダ)
・血友病A・B組換え因子補充療法の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・血友病A・B組換え因子補充療法のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・血友病A・B組換え因子補充療法の中南米市場規模2016-2027(メキシコ、ブラジル)
・血友病A・B組換え因子補充療法の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Pfizer、Novo Nordisk、Baxalta、Bayer、Biogen、CSL Behring、Emergent Biosolutions、Spark therapeutics、Uniqure)
・結論
【レポートの概要】

Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.

Market Analysis and Insights: Global Hemophilia A and B Recombinant Factor Replacement Therapy Market
The global Hemophilia A and B Recombinant Factor Replacement Therapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hemophilia A and B Recombinant Factor Replacement Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hemophilia A and B Recombinant Factor Replacement Therapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hemophilia A and B Recombinant Factor Replacement Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hemophilia A and B Recombinant Factor Replacement Therapy market.

Global Hemophilia A and B Recombinant Factor Replacement Therapy Scope and Market Size
Hemophilia A and B Recombinant Factor Replacement Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hemophilia A and B Recombinant Factor Replacement Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Haemophilia A
Haemophilia B

Segment by Application
Hospitals
Clinics
AmbulatorySurgicalCenters

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Haemophilia A
1.2.3 Haemophilia B
1.3 Market by Application
1.3.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 AmbulatorySurgicalCenters
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Perspective (2016-2027)
2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Growth Trends by Regions
2.2.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Share by Regions (2016-2021)
2.2.3 Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Regions (2022-2027)
2.3 Hemophilia A and B Recombinant Factor Replacement Therapy Industry Dynamic
2.3.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Trends
2.3.2 Hemophilia A and B Recombinant Factor Replacement Therapy Market Drivers
2.3.3 Hemophilia A and B Recombinant Factor Replacement Therapy Market Challenges
2.3.4 Hemophilia A and B Recombinant Factor Replacement Therapy Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Revenue
3.1.1 Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Revenue (2016-2021)
3.1.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Players (2016-2021)
3.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue
3.4 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Concentration Ratio
3.4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in 2020
3.5 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players Head office and Area Served
3.6 Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Product Solution and Service
3.7 Date of Enter into Hemophilia A and B Recombinant Factor Replacement Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hemophilia A and B Recombinant Factor Replacement Therapy Breakdown Data by Type
4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Size by Type (2016-2021)
4.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Type (2022-2027)

5 Hemophilia A and B Recombinant Factor Replacement Therapy Breakdown Data by Application
5.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Size by Application (2016-2021)
5.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2016-2027)
6.2 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
6.2.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021)
6.2.2 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027)
6.2.3 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2027)
6.3 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application
6.3.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021)
6.3.2 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027)
6.3.3 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2027)
6.4 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country
6.4.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021)
6.4.2 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2016-2027)
7.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
7.2.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021)
7.2.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027)
7.2.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2027)
7.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application
7.3.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021)
7.3.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027)
7.3.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2027)
7.4 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country
7.4.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021)
7.4.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2016-2027)
8.2 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
8.2.1 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application
8.3.1 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Region
8.4.1 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2016-2027)
9.2 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
9.2.1 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021)
9.2.2 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027)
9.2.3 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2027)
9.3 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application
9.3.1 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021)
9.3.2 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027)
9.3.3 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2027)
9.4 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country
9.4.1 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021)
9.4.2 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2016-2027)
10.2 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type
10.2.1 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application
10.3.1 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country
10.4.1 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.1.4 Pfizer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Details
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.2.4 Novo Nordisk Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.2.5 Novo Nordisk Recent Development
11.3 Baxalta
11.3.1 Baxalta Company Details
11.3.2 Baxalta Business Overview
11.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.3.4 Baxalta Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.3.5 Baxalta Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.4.4 Bayer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.4.5 Bayer Recent Development
11.5 Biogen
11.5.1 Biogen Company Details
11.5.2 Biogen Business Overview
11.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.5.4 Biogen Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.5.5 Biogen Recent Development
11.6 CSL Behring
11.6.1 CSL Behring Company Details
11.6.2 CSL Behring Business Overview
11.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.6.4 CSL Behring Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.6.5 CSL Behring Recent Development
11.7 Emergent Biosolutions
11.7.1 Emergent Biosolutions Company Details
11.7.2 Emergent Biosolutions Business Overview
11.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.7.4 Emergent Biosolutions Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.7.5 Emergent Biosolutions Recent Development
11.8 Spark therapeutics
11.8.1 Spark therapeutics Company Details
11.8.2 Spark therapeutics Business Overview
11.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.8.4 Spark therapeutics Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.8.5 Spark therapeutics Recent Development
11.9 Uniqure
11.9.1 Uniqure Company Details
11.9.2 Uniqure Business Overview
11.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
11.9.4 Uniqure Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
11.9.5 Uniqure Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Haemophilia A
Table 3. Key Players of Haemophilia B
Table 4. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions (2016-2021)
Table 8. Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions (2022-2027)
Table 10. Hemophilia A and B Recombinant Factor Replacement Therapy Market Trends
Table 11. Hemophilia A and B Recombinant Factor Replacement Therapy Market Drivers
Table 12. Hemophilia A and B Recombinant Factor Replacement Therapy Market Challenges
Table 13. Hemophilia A and B Recombinant Factor Replacement Therapy Market Restraints
Table 14. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Players (2016-2021)
Table 16. Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy as of 2020)
Table 17. Ranking of Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Product Solution and Service
Table 21. Date of Enter into Hemophilia A and B Recombinant Factor Replacement Therapy Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Type (2016-2021)
Table 25. Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Application (2016-2021)
Table 29. Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 61. Pfizer Company Details
Table 62. Pfizer Business Overview
Table 63. Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 64. Pfizer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Novo Nordisk Company Details
Table 67. Novo Nordisk Business Overview
Table 68. Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 69. Novo Nordisk Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 70. Novo Nordisk Recent Development
Table 71. Baxalta Company Details
Table 72. Baxalta Business Overview
Table 73. Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 74. Baxalta Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 75. Baxalta Recent Development
Table 76. Bayer Company Details
Table 77. Bayer Business Overview
Table 78. Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 79. Bayer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 80. Bayer Recent Development
Table 81. Biogen Company Details
Table 82. Biogen Business Overview
Table 83. Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 84. Biogen Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 85. Biogen Recent Development
Table 86. CSL Behring Company Details
Table 87. CSL Behring Business Overview
Table 88. CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 89. CSL Behring Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 90. CSL Behring Recent Development
Table 91. Emergent Biosolutions Company Details
Table 92. Emergent Biosolutions Business Overview
Table 93. Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 94. Emergent Biosolutions Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 95. Emergent Biosolutions Recent Development
Table 96. Spark therapeutics Company Details
Table 97. Spark therapeutics Business Overview
Table 98. Spark therapeutics Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 99. Spark therapeutics Recent Development
Table 100. Uniqure Company Details
Table 101. Uniqure Business Overview
Table 102. Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Product
Table 103. Uniqure Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021) & (US$ Million)
Table 104. Uniqure Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type: 2020 VS 2027
Figure 2. Haemophilia A Features
Figure 3. Haemophilia B Features
Figure 4. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. AmbulatorySurgicalCenters Case Studies
Figure 8. Hemophilia A and B Recombinant Factor Replacement Therapy Report Years Considered
Figure 9. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions: 2020 VS 2027
Figure 12. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions (2022-2027)
Figure 13. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Players in 2020
Figure 14. Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in 2020
Figure 16. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Type (2016-2021)
Figure 17. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Type (2022-2027)
Figure 18. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2016-2027)
Figure 20. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2016-2027)
Figure 21. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Country (2016-2027)
Figure 22. United States Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2016-2027)
Figure 26. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2016-2027)
Figure 27. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Country (2016-2027)
Figure 28. Germany Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Region (2016-2027)
Figure 38. China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2016-2027)
Figure 46. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2016-2027)
Figure 47. Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Country (2016-2027)
Figure 48. Mexico Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Country (2016-2027)
Figure 54. Turkey Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Pfizer Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 58. Novo Nordisk Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 59. Baxalta Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 60. Bayer Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 61. Biogen Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 62. CSL Behring Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 63. Emergent Biosolutions Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 64. Spark therapeutics Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 65. Uniqure Revenue Growth Rate in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed


【掲載企業】

Pfizer、Novo Nordisk、Baxalta、Bayer、Biogen、CSL Behring、Emergent Biosolutions、Spark therapeutics、Uniqure

★調査レポート[世界の血友病A・B組換え因子補充療法市場規模・現状・予測2021-2027] (コード:QY21APR2770)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の血友病A・B組換え因子補充療法市場規模・現状・予測2021-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆